The study by Jiang et al. [1] to determine the impact of laryngopharyngeal reflux disease (LPRD) on the clinical outcomes in hospitalized patients with novel coronavirus disease 2019 (COVID‐19) is first of its kind study in the literature. While available studies have mostly focused on the effect of cardiovascular comorbidities, the authors' work raises the concurrent gastrointestinal related issues in patients with COVID‐19. This article is protected by copyright. All rights reserved.
Could melatonin be used in COVID‐19 patients with laryngopharyngeal reflux disease?